R. Siegel, D. Naishadham, and A. Jemal, Cancer statistics, 2012, CA: A Cancer Journal for Clinicians, vol.287, issue.suppl 5, pp.10-29, 2012.
DOI : 10.1001/jama.287.16.2106
URL : http://onlinelibrary.wiley.com/doi/10.3322/caac.21332/pdf

S. Mabuchi, C. Kawase, D. Altomare, K. Morishige, M. Hayashi et al., Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary, Molecular Cancer Therapeutics, vol.9, issue.8, pp.2411-2433, 2010.
DOI : 10.1158/1535-7163.MCT-10-0169

R. Burger, Overview of anti-angiogenic agents in development for ovarian cancer, Gynecologic Oncology, vol.121, issue.1, pp.230-238, 2011.
DOI : 10.1016/j.ygyno.2010.11.035

B. Guerrouahen, J. Pasquier, N. Kaoud, M. Maleki, M. Beauchamp et al., Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer, Molecular Cancer Therapeutics, vol.13, issue.12, pp.3123-3159, 2014.
DOI : 10.1158/1535-7163.MCT-13-1053

M. Mirza, B. Monk, J. Herrstedt, A. Oza, S. Mahner et al., Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, New England Journal of Medicine, vol.375, issue.22, pp.2154-64, 2016.
DOI : 10.1056/NEJMoa1611310

C. Box, S. Rogers, M. Mendiola, and S. Eccles, Tumour-microenvironmental interactions: paths to progression and targets for treatment, Seminars in Cancer Biology, vol.20, issue.3, pp.128-166, 2010.
DOI : 10.1016/j.semcancer.2010.06.004

S. Tyan, W. Kuo, C. Huang, C. Pan, J. Shew et al., Breast Cancer Cells Induce Cancer-Associated Fibroblasts to Secrete Hepatocyte Growth Factor to Enhance Breast Tumorigenesis, PLoS ONE, vol.303, issue.1, p.15313, 2011.
DOI : 10.1371/journal.pone.0015313.s004

K. Levano, E. Jung, and P. Kenny, Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines, Biochemical and Biophysical Research Communications, vol.411, issue.1, pp.107-117, 2011.
DOI : 10.1016/j.bbrc.2011.06.102

R. Lis, C. Touboul, N. Halabi, A. Madduri, D. Querleu et al., Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile, Journal of Translational Medicine, vol.12, issue.1, p.59, 2014.
DOI : 10.1172/JCI45273

R. Lis, C. Touboul, C. Raynaud, J. Malek, K. Suhre et al., Mesenchymal Cell Interaction with Ovarian Cancer Cells Triggers Pro-Metastatic Properties, PLoS ONE, vol.474, issue.5, p.38340, 2012.
DOI : 10.1371/journal.pone.0038340.s002

C. Touboul, R. Lis, A. Farsi, H. Raynaud, C. Warfa et al., Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model, Journal of Translational Medicine, vol.11, issue.1, p.28, 2013.
DOI : 10.1158/0008-5472.CAN-10-0538
URL : https://hal.archives-ouvertes.fr/inserm-00794947

C. Touboul, F. Vidal, J. Pasquier, R. Lis, and A. Rafii, Role of mesenchymal cells in the natural history of ovarian cancer: a review, Journal of Translational Medicine, vol.36, issue.9737, p.271, 2014.
DOI : 10.1016/j.ejso.2010.04.005
URL : https://hal.archives-ouvertes.fr/inserm-01202727

J. Pasquier, N. Abu-kaoud, H. Abdesselem, A. Madani, J. Hoarau-vechot et al., SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interaction, BMC Cancer, vol.31, issue.12, p.569, 2015.
DOI : 10.1109/TMI.2012.2218116

A. Thawadi, H. Abu-kaoud, N. , A. Farsi, H. Hoarau-vechot et al., VE-cadherin cleavage by ovarian cancer microparticles induces betacatenin phosphorylation in endothelial cells, Oncotarget, vol.7, pp.5289-305, 2016.

P. Ghiabi, J. Jiang, J. Pasquier, M. Maleki, N. Abu-kaoud et al., Breast cancer cells promote a notch-dependent mesenchymal phenotype in endothelial cells participating to a pro-tumoral niche, Journal of Translational Medicine, vol.13, issue.1, p.27, 2015.
DOI : 10.1186/1471-2407-14-783

M. Iwanicki, R. Davidowitz, M. Ng, A. Besser, T. Muranen et al., Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium, Cancer Discovery, vol.1, issue.2, pp.144-57, 2011.
DOI : 10.1158/2159-8274.CD-11-0010

A. Caplan and S. Bruder, Mesenchymal stem cells: building blocks for molecular medicine in the 21st century, Trends in Molecular Medicine, vol.7, issue.6, pp.259-64, 2001.
DOI : 10.1016/S1471-4914(01)02016-0

A. Rafii, P. Mirshahi, M. Poupot, A. Faussat, A. Simon et al., Oncologic Trogocytosis of an Original Stromal Cells Induces Chemoresistance of Ovarian Tumours, PLoS ONE, vol.171, issue.2, p.3894, 2008.
DOI : 10.1371/journal.pone.0003894.s002

J. Pasquier, H. Thawadi, P. Ghiabi, N. Abu-kaoud, M. Maleki et al., Microparticles mediated cross-talk between tumoral and endothelial cells promote the constitution of a pro-metastatic vascular niche through Arf6 up regulation, Cancer Microenvironment, vol.14, issue.4, pp.41-59, 2014.
DOI : 10.1186/1479-5876-11-28

K. Mclean, Y. Gong, Y. Choi, N. Deng, K. Yang et al., Human ovarian carcinoma???associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production, Journal of Clinical Investigation, vol.121, issue.8, pp.3206-3225, 2011.
DOI : 10.1172/JCI45273DS1

N. Benabbou, P. Mirshahi, M. Cadillon, J. Soria, A. Therwath et al., Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer cell line, International Journal of Oncology, vol.43, issue.3, pp.685-94, 2013.
DOI : 10.3892/ijo.2013.2017

M. Castells, B. Thibault, E. Mery, M. Golzio, M. Pasquet et al., Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages, Cancer Letters, vol.326, issue.1, pp.59-68, 2012.
DOI : 10.1016/j.canlet.2012.07.020

W. Xu, Z. Bian, Q. Fan, G. Li, and T. Tang, Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis, Cancer Letters, vol.281, issue.1, pp.32-41, 2009.
DOI : 10.1016/j.canlet.2009.02.022

T. Ueno, M. Toi, H. Saji, M. Muta, H. Bando et al., Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer, Clin Cancer Res, vol.6, pp.3282-3291, 2000.

E. Neumark, O. Sagi-assif, B. Shalmon, A. Ben-baruch, and I. Witz, Progression of mouse mammary tumors: MCP-1-TNF? cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors, International Journal of Cancer, vol.7, issue.6, pp.879-86, 2003.
DOI : 10.1002/ijc.11337

J. Muller, S. Gorressen, M. Grandoch, K. Feldmann, I. Kretschmer et al., Interleukin-6-dependent phenotypic modulation of cardiac fibroblasts after acute myocardial infarction, Basic Research in Cardiology, vol.117, issue.6, p.440, 2014.
DOI : 10.1161/CIRCULATIONAHA.107.714147

T. Piltonen, J. Chen, M. Khatun, M. Kangasniemi, A. Liakka et al., Endometrial stromal fibroblasts from women with polycystic ovary syndrome have impaired progesterone-mediated decidualization, aberrant cytokine profiles and promote enhanced immune cell migration in vitro, Human Reproduction, vol.551, issue.(Suppl 2), pp.1203-1218, 2015.
DOI : 10.1016/j.gene.2014.08.047

L. Zimmerlin, T. Park, E. Zambidis, V. Donnenberg, and A. Donnenberg, Mesenchymal stem cell secretome and regenerative therapy after??cancer, Biochimie, vol.95, issue.12, pp.2235-2280, 2013.
DOI : 10.1016/j.biochi.2013.05.010
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825748/pdf

X. Wang, X. Yang, Y. Tsai, L. Yang, K. Chuang et al., IL-6 Mediates Macrophage Infiltration after Irradiation via Up-regulation of CCL2/CCL5 in Non-small Cell Lung Cancer, Radiation Research, vol.187, issue.1, pp.50-59, 2017.
DOI : 10.1667/RR14503.1

K. Anton, D. Banerjee, and J. Glod, Macrophage-Associated Mesenchymal Stem Cells Assume an Activated, Migratory, Pro-Inflammatory Phenotype with Increased IL-6 and CXCL10 Secretion, PLoS ONE, vol.25, issue.11, p.35036, 2012.
DOI : 10.1371/journal.pone.0035036.s002

P. Biswas, F. Delfanti, S. Bernasconi, M. Mengozzi, M. Cota et al., Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line, Blood, vol.91, pp.258-65, 1998.

E. Spaeth, J. Dembinski, A. Sasser, K. Watson, A. Klopp et al., Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression, PLoS ONE, vol.72, issue.4, p.4992, 2009.
DOI : 10.1371/journal.pone.0004992.s004

K. Rath, H. Funk, M. Bowling, W. Richards, and A. Drew, Expression of soluble interleukin-6 receptor in malignant ovarian tissue, American Journal of Obstetrics and Gynecology, vol.203, issue.3, pp.230-231, 2010.
DOI : 10.1016/j.ajog.2010.03.034

J. Coward, H. Kulbe, P. Chakravarty, D. Leader, V. Vassileva et al., Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer, Clinical Cancer Research, vol.17, issue.18, pp.6083-96, 2011.
DOI : 10.1158/1078-0432.CCR-11-0945

J. Burgos, M. Rosol, R. Moats, V. Khankaldyyan, D. Kohn et al., Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice, BioTechniques, vol.34, pp.1184-1192, 2003.

S. Kidd, E. Spaeth, J. Dembinski, M. Dietrich, K. Watson et al., Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent Imaging, Stem Cells, vol.116, issue.10, pp.2614-2637, 2009.
DOI : 10.1056/NEJM198612253152606

C. Milagre, G. Gopinathan, G. Everitt, R. Thompson, H. Kulbe et al., Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer, Cancer Research, vol.75, issue.7, pp.1255-64, 2015.
DOI : 10.1158/0008-5472.CAN-14-1801

E. Dijkgraaf, S. Santegoets, A. Reyners, R. Goedemans, M. Wouters et al., A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-??2b in patients with recurrent epithelial ovarian cancer, Annals of Oncology, vol.344, issue.10, pp.2141-2150, 2015.
DOI : 10.1006/gyno.1998.4974

D. Chauhan, P. Pandey, T. Hideshima, S. Treon, N. Raje et al., SHP2 Mediates the Protective Effect of Interleukin-6 Against Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells, Journal of Biological Chemistry, vol.275, pp.27845-50, 2000.
DOI : 10.1074/jbc.M003428200

C. Hsu, I. Lee, C. Lin, L. Hsiao, and C. Yang, /IL-6 Secretion via c-Src-Dependent AP-1 Activation, Journal of Cellular Physiology, vol.85, issue.3, pp.702-717, 2015.
DOI : 10.1016/j.bcp.2013.01.013

M. Meads, B. Fang, L. Mathews, J. Gemmer, L. Nong et al., Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma, Oncogene, vol.275, issue.21, pp.2723-2757, 2016.
DOI : 10.1021/pr1006203

K. Ward, I. Tancioni, C. Lawson, N. Miller, C. Jean et al., Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression, Clinical & Experimental Metastasis, vol.282, issue.5, pp.579-94, 2013.
DOI : 10.1074/jbc.M610672200

N. Shah, I. Tancioni, K. Ward, C. Lawson, X. Chen et al., Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer, Gynecologic Oncology, vol.134, issue.1, pp.104-115, 2014.
DOI : 10.1016/j.ygyno.2014.04.044

I. Tancioni, S. Uryu, F. Sulzmaier, N. Shah, C. Lawson et al., FAK Inhibition Disrupts a ??5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth, Molecular Cancer Therapeutics, vol.13, issue.8, pp.2050-61, 2014.
DOI : 10.1158/1535-7163.MCT-13-1063

S. Lim, N. Miller, J. Nam, X. Chen, Y. Lim et al., Pyk2 Inhibition of p53 as an Adaptive and Intrinsic Mechanism Facilitating Cell Proliferation and Survival, Journal of Biological Chemistry, vol.165, issue.3, pp.1743-53, 2010.
DOI : 10.1158/0008-5472.CAN-03-2820

D. Lane, I. Matte, C. Laplante, P. Garde-granger, A. Carignan et al., CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling, Molecular Cancer, vol.33, issue.1, p.58, 2016.
DOI : 10.1007/s13277-015-3825-0
URL : https://molecular-cancer.biomedcentral.com/track/pdf/10.1186/s12943-016-0542-2?site=molecular-cancer.biomedcentral.com

H. Yoon, Y. Choi, J. Song, I. Do, S. Kang et al., Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines, PLoS ONE, vol.24, issue.2, p.88587, 2014.
DOI : 10.1371/journal.pone.0088587.s004

T. Shimizu, K. Fukuoka, M. Takeda, T. Iwasa, T. Yoshida et al., A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, vol.48, issue.Suppl 6, pp.997-1003, 2016.
DOI : 10.1016/S0959-8049(12)72407-3

S. Jones, L. Siu, J. Bendell, J. Cleary, A. Razak et al., A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors, Investigational New Drugs, vol.32, issue.15 Supplement, pp.1100-1107, 2015.
DOI : 10.1016/S0002-9440(10)63370-6

M. Meads, R. Gatenby, and W. Dalton, Environment-mediated drug resistance: a major contributor to minimal residual disease, Nature Reviews Cancer, vol.112, issue.9, pp.665-74, 2009.
DOI : 10.1038/nrm1229